Emerging role of radiolabeled nanoparticles as an effective diagnostic technique

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-15

  de Barros, André Luís Branco ^a,b,c   Tsourkas, Andrew ^c   Saboury, Babak ^b   Cardoso, Valbert Nascimento ^a   Alavi, Abass ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular disease; Inflammation; Nanoparticles; PET imaging; SPECT imaging; Tumor

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CARBON; CARBON NANOPARTICLE; CYCLOPHOSPHAMIDE; DENDRIMER; DOXORUBICIN; ETOPOSIDE; GOLD NANOPARTICLE; LIPOSOME; MACROCYCLIC COMPOUND; NANOCAPSULE; NANOPARTICLE; PENTETATE INDIUM IN 111; QUANTUM DOT; SILICA NANOPARTICLE; SOLID LIPID NANOPARTICLE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ATHEROMA; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; ISOTOPE LABELING; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MICELLE; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULTRASOUND; X RAY;

EID: 84875352025     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-39     Document Type: Review

References (159)

1. Moghimi SM, Hunter AC, Murray JC: Nanomedicine: current status and future prospects. FASEB J 2005, 19:311-330.
2. Mailander V, Landfester K: Interaction of nanoparitcles with cells. Biomacromolecules 2009, 10:2379-2400.
3. Wagner V, Dullaart A, Bock A, Zweck A: The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
4. Kim BYS, Rutka JT, Chan WCW: Current concepts: nanomedicine. N Eng J Med 2010, 363:2434-2443.
5. Lewis DR, Kamisoglu K, York AW, Moghe PV: Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. WIREs Nanomed Nanobiotechnol 2011, 3:400-420.
6. Xia Y, Xiong Y, Lim B, Skrabalak SE: Shape-controlled synthesis of metal nanocrystals: simple chemistry meets complex physics? Angew Chem Int Ed 2009, 48:60-103.
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
8. Shenhar R, Norsten TB, Rotello VM: Polymer-mediated nanoparticle assembly: structural control and applications. Adv Mater 2005, 17:657-669.
9. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
10. Garbazenko O, Barenholz Y, Priev A: Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 2005, 135:117-129.
11. Cattel L, Ceruti M, Dosio F: From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 2003, 89:237-249.
12. Jokerst JV, Lobovkina T, Zare RN, Gambhir SV: Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6:715-728.
13. Gupta AS: Nanomedicine approaches in vascular disease: a review. Nanomedicine: Nanotech Biol Med 2011, 7:763-779.
14. Maeda H, Sawa T, Konno T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001, 74:47-61.
15. Torchilin V: Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Del Rev 2011, 63:131-135.
16. Fang J, Nakamure H, Maeda H: The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Del Rev 2011, 63:136-151.
17. Orive G, Ali OA, Anitua E, Pedraz JL, Emerich DF: Biomedical-based technologies for brain anti-cancer therapeutics and imaging. Biochim Biophys Acta 2010, 1806:96-107.
18. Lee H, Li Z, Chen K, Hsu AR, Xu C, Xie J, Sun S, Chen X: PET/MRI dualmodality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008, 49:1371-1379.
19. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R: Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005, 96:327-336.
20. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504-1511.
21. 159Gd: in vitro antitumoral activity. Biodistribution study and scintigraphic image in Ehrlich tumor bearing mice. Eur J Pharm Sci 2011, 43:290-296.
22. Saul JM, Annapragada AV, Bellamkonda RV: A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006, 114:277-287.
23. Ying X, Wen HE, Lu WL, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q: Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010, 141:183-192.
24. Sinusas AJ, Benjel F, Nahrendorf M, Epstein FH, Wu JC, Villanueva FS, Fayad ZA, Gropler RJ: Multimodality cardiovascular molecular imaging, Part I. Circ Cardiovasc Imaging 2008, 1:244-256.
25. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A: Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009, 39:124-145.
26. Hong H, Zhang Y, Sun J, Cai W: Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 2009, 4:399-413.
27. Ting G, Chang C, Wang H: Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res 2009, 29:4107-4118.
28. Bangham AD, Standish MM, Watkins JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965, 13:238-252.
29. De Barros ALB, Mota LG, Soares DCF, Coelho MMA, Oliveira MC, Cardoso VN: Tumor bombesin analog loaded long-circulating and pH-sensitive liposomes as tool for tumor identification. Bioorg Med Chem Lett 2011, 21:7373-7375.
30. Damen J, Regts J, Scherphof G: Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. Biochim Biophys Acta 1981, 665:538-545.
31. Sahoo SK, Labhasetwar V: Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8:1112-1120.
32. Senior J, Gregoriadis G: Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett 1982, 145:109-114.
33. Soenen SJH, Brisson AR, DeCuyper M: Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 2009, 30:3691-3701.
34. Mufamadi MS, Pillay V, Choonara YE, Du Toit LC, Modi G, Naidoo D, Ndesendo MK: A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv 2011, 2011:939851.
35. Torchilin VP: Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008, 60:548-558.
36. Li X, Ding L, Xu Y, Wang Y, Ping Q: Targeted delivery of doxorubicin using stealth liposomes modified with transferring. Int J Pharm 2009, 373:116-123.
37. Song CK, Jung SH, Kim DD, Jeong KS, Shin BC, Seong H: Disaccharidemodified liposomes and their in vitro intracellular uptake. Int J Pharm 2009, 380:161-169.
38. Shmeeda H, Amitay Y, Gorin J, Tzemach D, Mak L, Ogorka J, Kumar S, Zhang JA, Gabizon A: Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release 2010, 146:76-83.
39. Júnior ADC, Mota LG, Numan EA, Wainstein AJA, Wainstein APDI, Leal AS, Cardoso VN, Oliveira MC: Tissue distribution evaluation of stealth pHsensitive liposomal cisplatin versus free cisplatin in Ehrlich tumorbearing mice. Life Sci 2007, 80:659-664.
40. Cho EC, Lim HJ, Kim HJ, Son ED, Choi HJ, Park JH, Kim JW, Kim J: Role of pH-sensitive polymer-liposome complex in enhancing cellular uptake of biologically active drugs. Mater Sci Eng 2009, 29:774-778.
41. Oku N, Tokudome Y, Tsukada H, Okada S: Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. Biochim Biophys Acta 1995, 1238:86-90.
42. 64Cu for positron emission tomography (PET) imaging. Bioconjugate Chem 2008, 19:2577-2584.
43. 99mTc-labelled stealth pH-sensitive liposomes. Nucl Med Commun 2008, 29:33-38.
44. Marik J, Tartis MS, Zhang H, Fung JY, Kheirolomoom A, Sutcliffe JL, Ferrara KW: Long-circulating liposomes radiolabeled with [18 F]fluorodipalmitin ([18 F]FDP). Nucl Med Biol 2007, 34:165-171.
45. Li S, Goins B, Zhang L, Bao A: Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjugate Chem 2012, 23:1322-1332.
46. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J NucI Med 2000, 41:622-630.
47. Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang B, Mehta JL, Beller GA, Glover DK, Meyer CH: Molecular imaging of atherosclerosis plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging 2010, 3:464-472.
48. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart SW: Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001, 7:243-254.
49. 188Re-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 2007, 27:2217-2226.
50. 64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials 2011, 32:2334-2341.
51. Pankhurst QA, Connolly J, Jones SK, Dobson J: Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 2003, 36:R167.
52. Amstad E, Textor M, Reimhult E: Stabilization and functionalization of iron oxide nanoparticles for medical applications. Nanoscale 2011, 3:2819-2843.
53. Choi HS, Liu W, Mirsa P, Tanaka E, Zimmer JP, Ipe BI, Bawendi MG, Frangioni JV: Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
54. Neuberger T, Schopf B, Hofmann H, Hofmann M, von Rechenberg B: Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater 2005, 293:483-496.
55. Laurent S, Forge D, Port M, Roch A, Robic C, Elst LV, Muller RN: Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterization, and biological applications. Chem Rev 2008, 108:2064-2110.
56. McAteer MA, Akhtar AM, Muhlen C, Choudhury RP: An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis 2010, 209:18-27.
57. Elias A, Tsourkas A: Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles. Hematology Am Soc Hematol Educ Program 2009, 2009:720-726.
58. Thorek DLJ, Tsourkas A: Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 2008, 29:3583-3590.
59. McCarthy JR, Weissleder R: Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008, 11:1241-1251.
60. McCarthy JR, Bhaumik J, Karver MR, Erdem SS, Weissleder R: Target nanoagents for the detection of cancer. Mol Oncol 2010, 4:511-528.
61. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L: Magneto/optical annexin V, a multimodal protein. Bioconjug Chem 2004, 15:1062-1067.
62. Moore A, Medarova Z, Potthast A, Dai G: In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004, 64:1821-1827.
63. Quinti L, Weissleder R, Tung CH: A fluorescent nanosensor for apoptotic cells. Nano Lett 2006, 6:488-490.
64. Nahrendorf M, Keliher E, Marinelli B, Waterman P, Feruglio PF, Fexon L, Pivovarov M, Swirski FK, Pittet MJ, Vinegoni C, Weissleder R: Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci 2010, 107:7910-7915.
65. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biological evaluation. J Nucl Med 2005, 46:1210-1218.
66. Shokeen M, Fettig NM, Rossin R: Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles. Q J Nucl Med Mol Imaging 2008, 52:267-277.
67. Jalilian AR, Panahifar A, Mahmoudi M, Akhlaghi M, Simchi A: Preparation and biological evaluation of [67 Ga]-labeled-superparamagnetic nanoparticles in normal rats. Radiochim Acta 2009, 97:51-56.
68. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjugate Chem 2009, 20:397-401.
69. 99mTcbisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. Bioconjugate Chem 2011, 22:455-465.
70. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD: Fast and robust registration of PET and MR images of human brain. NeuroImage 2004, 22:434-442.
71. Myers R: The application of PET-MR images registration in the brain. Br J Radiol 2002, 75:S31-S35.
72. Mahmoudi M, Serpooshan V, Laurent S: Enginner nanoparticles for biomolecular imaging. Nanoscale 2011, 3:3007-3026.
73. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, Li X, Chen X: PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010, 31:3016-3022.
74. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, AIkawa E, Libby P, Swirski FK, Weissleder R: Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 177:379-387.
75. Narehdorf M, Keliher E, Marinelli B, Leuschner F, Robins CS, Gerszten RE, Pittet MJ, Swirski FK, Weissleder R: Detection of macrophages in aortic aneurysms by nanoparticle PET-CT. Aterioscler Thromb Vasc Biol 2011, 31:750-757.
76. Hutter E, Maysinger D: Gold nanoparticles and quantum dots for bioimaging. Microsc Res Tech 2011, 74:592-604.
77. Thakor AS, Jokerst J, Zavaleta C, Massoud TF, Gambhir SS: Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett 2011, 11:4029-4036.
78. Turkevich J, Steverson PC, Hillier J: A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951, 11:55-75.
79. 3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomed 2011, 6:259-269.
80. Agarwal A, Shao X, Rajian JR, Zhang H, Chamberland DL, Kotov NA, Wang X: Dual-mode imaging with radiolabeled gold nanorods. J Biomed Opt 2011, 16:051307.
81. 125I-labeled gold nanoparticles. Nanotechnology 2011, 13:135102.
82. Guerrero S, Herance JR, Rojas S, Mena JF, Gispert JD, Acosta GA, Albericio F, Kogan MJ: Synthesis and in vivo evaluation of the biodistribution of a 18F-labeled conjugate gold-nanoparticle-peptide with potential biomedical applications. Bioconjugate Chem 2012, 23:399-408.
83. Xie H, Wang ZJ, Bao A, Goins B, Phillips WT: In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts. Int J Pharm 2010, 395:324-330.
84. 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. Bioconjugate Chem 2011, 22:913-922.
85. 125I-labeled gold nanorods for targeted imaging of inflammation. ACS Nano 2011, 5:8967-8973.
86. Janib SM, Moses AS, MacKay JA: Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010, 62:1052-1063.
87. Talelli M, Rijcken CJ, van Nostrum CF, Storm G, Hennink WE: Micelles based on HPMA copolymers. Adv Drug Deliv Rev 2010, 62:231-239.
88. Yokoyama M: Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. J Exp Clin Med 2011, 3:151-158.
89. Nishiyama N, Kataoka K: Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Therapeut 2006, 112:630-648.
90. Koo OM, Rubinstein I, Onyuksel H: Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine: Nanotechnol Biol Med 2005, 1:193-212.
91. Trubetskoy VS, Frank-Kamenetsky MD, Whiteman KR, Wolf GL, Torchilin VP: Stable polymeric micelles: lymphangiographic contrast media for gamma scintigraphy and magnetic resonance imaging. Acad Radiol 1996, 3:232-238.
92. Patil RR, Yu J, Banerjee SR, Ren Y, Leong D, Jiang X, Pomper M, Tsui B, Kraitchman DL, Mao HQ: Probing in vivo trafficking of polymer/DNA micellar nanoparticles using SPECT/CT imaging. Mol Ther 2011, 19:1626-1635.
93. Zhang R, Xiong C, Huang M, Zhou M, Huang Q, Wen X, Liang D: Peptideconjugated polymeric micellar nanoparticles for dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials 2011, 32:5872-5879.
94. Hoang B, Reilly RM, Allen C: Block copolymer micelles target auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells. Biomacromolecules 2012, 13:455-465.
95. Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, Li C: Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med 2011, 52:958-964.
96. Xiao Y, Hong H, Javadi A, Engle JW, Xu W, Yang Y, Zhang Y, Bernhart TE, Cai W, Gong S: Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
97. Iijima S: Helical microtubles of graphitic carbon. Nature (London) 1991, 354:56-58.
98. Chen RJ, Bangsaruntip S, Drouvalakis KA, Kam NWS, Shim M, Li YM, Kim W, Utz PJ, Dai HJ: Noncovalent functionalization of carbon nanotubes for highly specific electronic biosensors. Proc Nat Acad Sci 2003, 29:4984-4989.
99. Cherukuri P, Bachilo SM, Litovsky SH, Weisman RB: Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells. J Am Chem Soc 2004, 126:15638-15639.
100. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M, Bianco A, Kostarelos K: Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Nat Acad Sci 2006, 28:3357-3362.
101. Lacerda L, Soundararajan A, Singh R, Pastorin G, Al-Jamal KT, Turton J, Frederik P, Herrero MA, Li S, Bao A, Emfietzoglou D, Mather S, Phillips WT, Prato M, Bianco A, Goins B, Kostarelos K: Dynamic imaging of functionalized multi-walled carbon nanotube systemic circulation and urinary excretion. Adv Mater 2008, 20:225-230.
102. Deng XY, Yang ST, Nie HY, Wang HF, Liu YF: A generally adoptable radiotracing method for tracking carbon nanotubes in animals. Nanotechnology 2008, 19:075101.
103. Wang HF, Wang J, Deng XY, Sun HF, Shi ZJ, Gu ZN, Liu YF, Zhao YL: Biodistribution of carbon single-wall carbon nanotubes in mice. J Nanosci Nanotechnol 2004, 4:1019-1024.
104. Deng X, Jia G, Wang H, Sun H, Wang X, Yang S, Wang T, Liu Y: Translocation and fate of multi-walled carbon nanotubes in vivo. Carbon 2007, 45:1419-1424.
105. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA: Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007, 48:1180-1189.
106. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H: In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007, 2:47-52.
107. Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR: Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomed 2010, 5:783-802.
108. Bosi S, Ros TD, Spalluto G, Prato M: Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem 2003, 5:913-923.
109. Partha R, Conyers JL: Biomedical applications of functionalized fullerrenebased nanomaterials. Int J Nanomed 2009, 4:261-275.
110. Shinohara H: Endohedral metallofullerenes. Rep Prog Phys 2000, 63:843-892.
111. Cagle DW, Kennel SJ, Mirzadeh S, Alford JM, Wilson LJ: In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci USA 1999, 96:5182-5187.
112. x and its biodistribution studies. Nucl Med Biol 2002, 29:707-710.
113. 80: an interleukin-13-conjugated radiolabeled metallofullerene platform. J Am Chem Soc 2010, 132:4980-4981.
114. 60 nanocrystals. Nanotechnology 2009, 20:385102.
115. Caruthers SD, Cyrus T, Winter PM, Wickline AS, Lanza GM: Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. WIREs Nanomed Nanobiotechnol 2009, 1:311-323.
116. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hu G, Schmieder AH, Wickline AS: Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 2010, 13:182-202.
117. 111In nanoparticles. Int J Cancer 2007, 120:1951-1957.
118. Yang K, Wan J, Zhang S, Tian B, Zhang Y, Liu Z: The influence of surface chemistry and size of nanoscale graphene oxide on photothermal therapy of cancer using ultra-low laser power. Biomaterials 2012, 33:2206-2214.
119. Liu Z, Robinson JT, Sun X, Dai H: PEGylated nanographene oxide for delivery of water insoluble cancer drugs. J Am Chem Soc 2008, 130:10876-10877.
120. Sun X, Liu Z, Welsher K, Robinson JT, Goodwin A, Zaric S, Dai H: Nanographene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
121. Yang X, Zhang X, Liu Z, Ma Y, Huang Y, Chen Y: High efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. J Phys Chem C 2008, 112:17554-17558.
122. Lu CH, Yang HH, Zhu CL, Chen X, Chen GN: A graphene platform for sensing biomolecules. Angew Chem Int Ed 2009, 48:4785-4787.
123. Loh KP, Bao Q, Eda G, Chhowalla M: Graphene oxide as a chemically tunable platform for optical applications. Nat Chem 2010, 2:1015-1024.
124. Yang K, Wan J, Zhang S, Zhang Y, Lee ST, Liu Z: In vivo pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice. ACS Nano 2011, 5:516-522.
125. Zhang X, Yin J, Peng C, Hu W, Zhu Z, Li W, Fan C, Huang Q: Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon 2011, 49:986-995.
126. Hong H, Zhang Y, Engle JW, Nayak TR, Theuer CP, Nickles RJ, Bernhart TE, Cai W: In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene. Biomaterials 2012, 33:4147-4156.
127. Koo H, Huh MS, Ryu JH, Lee D, Sun I, Choi K, Kim K, Kwon IC: Nanoprobes for biomedical imaging in living systems. Nano Today 2011, 6:204-220.
128. Sakamoto JH, van de Ven AL, Godin B, Blanco E, Serda RE, Grattoni A, Ziemys A, Bouamrami A, Hu T, Ranganathan SI, Rosa E, Martinez IO, Smid CA, Buchanan RM, Lee SY, Srinivasan S, Landry M, Meyn A, Tasciotti E, Liu X, Decussi P, Ferrari M: Enabling individualized therapy through nanotechnology. Pharmacol Res 2010, 62:57-89.
129. 125mTe/ZnS nanoparticles. Nanotechnology 2007, 18:175103.
130. 125mTe/ZnS nanoparticles in vivo. Nucl Med Biol 2008, 35:501-514.
131. Schipper ML, Iyer G, Koh AL, Chang Z, Ebenstein Y, Aharoni A, Keren S, Bentolila LA, Li J, Rao J, Chen X, Banin U, Wu AM, Sinclair R, Weiss S, Gambhir SS: Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009, 5:126-134.
132. Ducongé F, Pons T, Pestourie C, Hérin L, Thézé B, Gombert K, Mahler B, Hinnen F, Kuhnast B, Dolle F, Dubertret B, Tavitian B: Fluorine-18-labeled phospholipid quantum dot micelles for in vivo multimodal imaging from whole body to cellular scales. Bioconjugate Chem 2008, 19:1921-1926.
133. Cai W, Chen K, Li Z, Gambhir SS, Chen X: Dual-function probe for PET and near-infrared fluorescene imaging of tumor vasculature. J Nucl Med 2007, 48:1862-1870.
134. Chen K, Li Z, Wang H, Cai W, Chen X: Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 2008, 35:2235-2244.
135. Menjoge AR, Kannan RM, Tomalia DA: Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010, 15:171-186.
136. Svenson S, Tomalia DA: Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005, 57:2106-2129.
137. Cheng Y, Gao Y, Rao T, Li Y, Xu T: Dendrimer-based prodrugs: design, synthesis, screening and biological evaluation. Comb Chem High Throughput Screen 2007, 10:336-349.
138. Agashe HB, Babbar AK, Jain S, Sharma RK, Misha AK, Asthana A, Grag M, Dutta T, Jain NK: Investigation on biodistribution of technetium-99mlabeled carbohydrate-coated poly(propylene imine) dendrimers. Nanomedicine: Nanotechnol Biol Med 2007, 3:120-127.
139. Kobayashi H, Wu C, Kim MK, Paik CH, Carrasquillo JA, Brechbiel MW: Evaluation of the in vivo biodistribution of Indium-111 and Yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. Bioconjugate Chem 1999, 10:103-111.
140. 111In-labeled oligo-DNA with avidin or avidin-dendrimer complex. J Control Release 2004, 95:133-141.
141. Kobayashi H, Koyama Y, Barrett T, Hama Y, Regino CA, Shin IS, Jang BS, Le N, Palk CH, Choyke PL, Urano Y: Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano 2007, 1:258-264.
142. Hagooley A, Almutairi A, Rossin R, Shokeen M, Ananth A, Anderson C, Abendschein D, Fréchetet Welch M: Evaluation of a RGD-dendrimer labeled with 76Br in hindlimb ischemia mouse model. J Nucl Med 2008, 49:184.
143. Parrot MC, Benhabbour SR, Saab C, Lemon JA, Parker S, Valliant JF, Adronov A: Synthesis, radiolabeling, and bio-imaging of high-generation polyester dendrimers. J Am Chem Soc 2009, 131:2906-2916.
144. Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D, Anderson CJ, Welch MJ, Fréchet JMJ: Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci 2009, 106:685-690.
145. Zhang Y, Sun Y, Xu X, Zhang X, Zhu H, Huang L, Qi Y, Shen YM: Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates. J Med Chem 2010, 53:3262-3272.
146. Legrand P, Barratt G, Mosqueira V, Fessi H, Devissaguet JP: Polymeric nanocapsules as drug delivery systems. A review. STP Pharma Sci 1999, 9:411-418.
147. 99mTechnetium-fluconazole nanocapsules. Int J Pharm 2008, 349:152-160.
148. Cahouet A, Denizot B, Hindré F, Passirani C, Heurtault B, Moreau M, Le Jeune JJ, Benoît JP: Biodistribution of dual radiolabeled lipidic nanocapsules in the rat using scintigraphy and γ counting. Int J Pharm 2002, 242:367-371.
149. Jestin E, Mougin-Degraef M, Faivre-Chauvet A, Saëc PR, Hindre F, Benoit JP, Chatal JF, Barbet J, GEstin JF: Radiolabeling and targeting of lipidic nanocapsules for application in radioimmunotherapy. Q J Nucl Med Mol Imaging 2007, 51:51-60.
150. 99mTechnetium-HMPAO: release properties and physicochemical characterization by atomic force microscopy and photon correlation spectroscopy. Eur J Pharm Sci 2008, 33:42-51.
151. 99mTc-HMPAO. Nucl Med Commun 2009, 30:749-755.
152. Anton N, Benoit JP, Saulnier P: Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 2008, 128:185-199.
153. 64Cu for positron emission tomography imaging. Bioconjugate Chem 2011, 22:808-818.
154. Liu Y, Mi Y, Zhao J, Feng S: Multifunctional silica nanoparticles for targeted delivery of hydrophobic imaging and therapeutic agents. Int J Pharm 2011, 421:370-378.
155. Tsai C, Chen C, Hung Y, Chang F, Mou C: Monoclonal antibodyfunctionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J Mater Chem 2009, 19:5737-5743.
156. Zhao Y, Sun X, Zhang G, Trewyn BG, Slowing II, Lin VS: Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 2011, 5:1366-1375.
157. Tang F, Li L, Chen D: Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 2012, 24:1504-1534.
158. Hudson SP, Padera RF, Langer R, Kohane DS: The biocompatibility of mesoporous silicates. Biomaterials 2008, 29:4045-4055.
159. Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, Destanchina E, Longo V, Herz E, Lyer S, Wolchok J, Larson SM, Wiesner U, Bradbury MS: Multimodal silica nanoparticles are effective cancertargeted probes in a model of human melanoma. J Clin Invest 2011, 121:2768-2786.